FDA accepts New Drug Application for Roche’s giredestrant in ER-positive early-stage breast cancer, the first and only oral SERD with positive phase III results in the curative setting roche.com
Roche to present new data advancing its obesity portfolio at the American Diabetes Association’s 2026 Scientific Sessions roche.com
Roche launches the Liver Disease Panel, the first suite of certified algorithms to support Chronic Liver Disease management roche.com
Roche to present new data at ASCO 2026, reinforcing giredestrant's potential to transform the treatment paradigm in early breast cancer roche.com
Roche receives CE mark for new blood test to detect Alzheimer's pathology: Elecsys® plasma phosphorylated-tau 217 (pTau217) roche.com
Roche enters into a definitive merger agreement to acquire PathAI to transform AI-driven diagnostics roche.com
Roche to present extensive data showcasing its industry-leading ophthalmology portfolio at ARVO 2026 roche.com
[Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong sales growth of +6% at constant exchange rates in the first quarter of 2026; -5% in CHF due to the significant appreciation of the Swiss franc roche.com
Roche’s fenebrutinib significantly reduced relapses versus standard of care to approximately one every 17 years in RMS roche.com
Roche’s ENSPRYNG (satralizumab) reduces risk of relapses by 68% demonstrating potential to become first treatment for MOGAD roche.com
